Lorus Completes IND-Enabling Toxicology Studies for Lead Small Molecule Anticancer Drug LOR-253
Complete the form below to unlock access to ALL audio articles.
Lorus Therapeutics Inc. has announced the successful completion of toxicology studies for its lead small molecule LOR-253 anticancer drug, formerly known as LT-253. LOR-253 represents a new targeted approach in cancer drug development, by inducing KLF4, a tumor suppressor factor that is reduced in a variety of important cancers.
The GLP, IND-enabling toxicology studies conducted for LOR-253 included maximum tolerated dose studies and repeat-dose toxicity studies in rodents and nonrodents. The data have established the toxicity profile for LOR-253, which will be supportive of a Phase I clinical trial in cancer patients.
Importantly, the study results indicate that LOR-253 is well tolerated at higher dose levels than efficacious dose levels determined from preclinical pharmacology studies.
The toxicology studies were designed to support the dosing regimen and intravenous route of administration for LOR-253 that is planned for a Phase I clinical trial upon filing an investigational new drug (IND) submission with the U.S. FDA.
"The successful completion of the toxicology program for LOR-253 is an important milestone in the development of this novel drug candidate which represents a "first in class" development program", said Dr Aiping Young, Lorus' President and CEO. "We are now one step closer to initiating clinical trials with this exciting compound, which was identified at Lorus using our drug discovery platform".
